Wordt geladen...
How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
IN BRIEF As more patents on biological medicines expire, increased numbers of biologic copies, referred to as “biosimilars,” will likely become available in the United States in the coming years. With greater availability and the drive for health care savings, the use of biosimilars and of “follow-o...
Bewaard in:
| Gepubliceerd in: | Clin Diabetes |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Diabetes Association
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5669137/ https://ncbi.nlm.nih.gov/pubmed/29109610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/cd16-0072 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|